Featured Research

from universities, journals, and other organizations

Research Holds Promise For Novel Oral Anti-diabetic Drugs

Date:
June 15, 2009
Source:
The Hebrew University of Jerusalem
Summary:
Promise is held out for the development of novel oral drugs to control blood glucose levels in diabetes patients as the result of research by a Hebrew University of Jerusalem scientist.

Prof. Shlomo Sasson is from the Hebrew University of Jerusalem.
Credit: Hebew University photo by Sasson Tiram

Promise is held out for the development of novel oral drugs to control blood glucose levels in diabetes patients as the result of research by a Hebrew University of Jerusalem scientist.

For his groundbreaking work, Prof. Shlomo Sasson of the Hebrew University School of Pharmacy has been named one of the winners this year of the Hebrew University's Kaye Innovation Awards.

Type 2 diabetes is a worldwide epidemic, predicted to affect over 380 million people within the next 20 years. This disease is characterized by high blood glucose levels that lead to severe complications in various organs and tissues. The disease usually results from insufficient secretion and function of the pancreatic hormone insulin that regulates glucose metabolism in peripheral tissues, such as skeletal muscles, fatty tissues and the liver.

Pharmacological anti-diabetic therapy aims at a strict regulation of blood glucose levels to prevent such complications. However, because current oral anti-diabetic drugs often fail, many patients need daily injections of insulin to control their glucose metabolism and reduce blood glucose levels.

The global diabetes therapy market is estimated at around US$26.3 billion in 2009. By 2013 the market is expected to grow to around US$34.5 billion.

Recent work on the molecular mechanisms that regulate glucose transport in skeletal muscles has identified new potential targets for anti-diabetic drugs.

In his research, Sasson, with his colleagues and students, made a unique discovery that high levels of the carbohydrate D-xylose increased the rate of glucose entry into skeletal muscle cells in a non-insulin-dependent manner. They then used it as a prototype molecule for the planning and synthesis of chemical derivatives that may act as potential drugs to lower blood glucose in type 2 diabetic patients.

Some of these derivatives increased significantly the rate of glucose transport in skeletal muscles at very low concentrations. This effect was not achieved by mimicking the classical pathway of insulin action, but by activating the enzyme AMP-activated protein kinase (AMPK). When activated, this enzyme increases the rate of glucose transport in skeletal muscles in the absence of insulin. Therefore, compounds that activate this enzyme can be effective in insulin resistant type 2 diabetic patients or in those that fail to respond to conventional drug therapy. This makes AMPK an extremely attractive target in the development of novel anti-diabetic drugs.

One of the lead compounds developed by Sasson and colleagues effectively reduced blood glucose levels in various animal models of diabetes. This discovery indicates the great potential of these novel derivatives to serve as the basis for development of new drugs to normalize blood glucose levels in diabetic patients.


Story Source:

The above story is based on materials provided by The Hebrew University of Jerusalem. Note: Materials may be edited for content and length.


Cite This Page:

The Hebrew University of Jerusalem. "Research Holds Promise For Novel Oral Anti-diabetic Drugs." ScienceDaily. ScienceDaily, 15 June 2009. <www.sciencedaily.com/releases/2009/06/090615093933.htm>.
The Hebrew University of Jerusalem. (2009, June 15). Research Holds Promise For Novel Oral Anti-diabetic Drugs. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2009/06/090615093933.htm
The Hebrew University of Jerusalem. "Research Holds Promise For Novel Oral Anti-diabetic Drugs." ScienceDaily. www.sciencedaily.com/releases/2009/06/090615093933.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com
Raw: Elephant Undergoes Surgery in Tbilisi Zoo

Raw: Elephant Undergoes Surgery in Tbilisi Zoo

AP (Sep. 18, 2014) Grand the elephant has successfully undergone surgery to remove a portion of infected tusk at Tbilisi Zoo in Georgia. British veterinary surgeons used an electric drill to extract the infected piece. (Sept. 18) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins